Stocktoria
Neuraxis, INC NRXS
Neuraxis, INC (NRXS) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.6M at a -218.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.48 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| NRXS | Neuraxis, INC | 3/9 | — | — | — |
| HCIL | Hongchang International Co., Ltd | 2/9 | 2.23 | — | — |
| GTHP | GUIDED THERAPEUTICS INC | 3/9 | — | — | — |
| ITOC | iTonic Holdings Ltd | 1/9 | 5.57 | — | — |
| POSC | POSITRON CORP | 2/9 | — | — | — |
| NXL | Nexalin Technology, Inc. | 4/9 | — | — | — |
| ENDV | ENDONOVO THERAPEUTICS, INC. | 3/9 | — | — | — |
About Neuraxis, INC
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
FAQ
Is NRXS financially healthy?
Neuraxis, INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does NRXS pay a dividend?
No, Neuraxis, INC does not currently pay a dividend.
How profitable is NRXS?
In FY2025, Neuraxis, INC had a net margin of -218.5% and a return on equity of -229.5%.
What is the analyst price target for NRXS?
The average Wall-Street price target for Neuraxis, INC is $11.00, about 75.4% above the recent price, from 2 analysts.
Is NRXS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Neuraxis, INC: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.